Pille Harrison

5.6k citations

53 papers · 2.0k indexed · 1 hit paper · h-index 19

Rheumatology top 0.5%
Immunology top 5%
Genetics top 5%
Oncology top 10%
Hematology top 2%

Co-authors: Chantal Tasset Annegret Van der Aa David M. Reid Anne Barton Ann W Morgan Wendy Thomson Jane Worthington Lynne J. Hocking
Topics: Chronic Lymphocytic Leukemia Research (19 papers)Rheumatoid Arthritis Research and Therapies (15 papers)Chronic Myeloid Leukemia Treatments (9 papers)
Cited by: Rheumatology Hematology Genetics
Journals: The Lancet Nature Genetics Gastroenterology
Partner nations: United Kingdom Belgium United States

In The Last Decade

Pille Harrison

52 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

2016 344 citations Séverine Vermeire, Stefan Schreiber et al. The Lancet profile →

Peers

Countries citing papers authored by Pille Harrison

Since Specialization

Citations

This map shows the geographic impact of Pille Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pille Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pille Harrison more than expected).

Fields of papers citing papers by Pille Harrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pille Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pille Harrison. The network helps show where Pille Harrison may publish in the future.

Co-authorship network of co-authors of Pille Harrison

This figure shows the co-authorship network connecting the top 25 collaborators of Pille Harrison. A scholar is included among the top collaborators of Pille Harrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pille Harrison. Pille Harrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes 2018 ·Arthritis Research & Therapy ·Mark C. Genovese,René Westhovens,Luc Meuleners,Annegret Van der Aa,Pille Harrison,Chantal Tasset,Arthur Kavanaugh	44
2	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial 2018 ·The Lancet ·Philip J. Mease,Laura C. Coates,Philip Helliwell,Mykola Stanislavchuk,(unknown),Anna Dudek,Walid Abi‐Saab,Chantal Tasset,Luc Meuleners,Pille Harrison,R. Besuyen,Annegret Van der Aa,Neelufar Mozaffarian,Joy M. Greer,Rebecca Kunder,Filip Van den Bosch,Dafna D. Gladman	156
3	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) 2016 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh,Joel M. Kremer,(unknown),Regina Cseuz,O. V. Reshetko,Mykola Stanislavchuk,Maria Greenwald,Annegret Van der Aa,Frédéric Vanhoutte,Chantal Tasset,Pille Harrison	176
4	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions 2016 ·Drug Metabolism Letters ·Florence Namour,Julie Desrivot,Annegret Van der Aa,Pille Harrison,Chantal Tasset,(unknown)	52
5	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialbreakdown → 2016 ·The Lancet ·Séverine Vermeire,Stefan Schreiber,Robert Petryka,Tanja Kuehbacher,Xavier Hébuterne,Xavier Roblin,Maria Kłopocka,Adrian Goldiș,Maria Wiśniewska‐Jarosińska,Andrey Baranovsky,Róbert Sike,(unknown),Chantal Tasset,Annegret Van der Aa,Pille Harrison	344
6	OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic 2012 ·Gut ·Vipul Jairath,David P. Hall,Pille Harrison,S.J. Stanworth,Tanya Walsh,(unknown),Jane Collier,Michael Murphy,Eleanor Barnes	2
7	PWE-294 Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy 2012 ·Gut ·Vipul Jairath,Pille Harrison,S.J. Stanworth,Jane Collier,(unknown),Eleanor Barnes	1
8	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease 2010 ·Arthritis Research & Therapy ·Stephen Eyre,Anne Hinks,John Bowes,Edward Flynn,Paul Martin,Anthony G. Wilson,Ann W Morgan,Paul Emery,Sophia Steer,Lynne J. Hocking,David M. Reid,Pille Harrison,P Wordsworth,Wendy Thomson,Jane Worthington,Anne Barton	78
9	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes 2010 ·Human Molecular Genetics ·Anne Barton,Stephen Eyre,(unknown),Anne Hinks,John Bowes,(unknown),(unknown),(unknown),Ann W Morgan,Paul Emery,(unknown),Lynne J. Hocking,(unknown),Pille Harrison,(unknown),Wendy Thomson,Jane Worthington	5
10	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes 2009 ·Human Molecular Genetics ·Anne Barton,Stephen Eyre,Xiayi Ke,Anne Hinks,John Bowes,Edward Flynn,Paul Martin,Anthony G. Wilson,Ann W Morgan,Paul Emery,Sophia Steer,Lynne J. Hocking,David M. Reid,Pille Harrison,P Wordsworth,Wendy Thomson,Jane Worthington	61
11	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23 2009 ·Human Molecular Genetics ·Gisela Orozco,Anne Hinks,Stephen Eyre,Xiayi Ke,Laura J. Gibbons,John Bowes,Edward Flynn,Paul Martin,Anthony G. Wilson,D E Bax,Ann W Morgan,Paul Emery,Sophia Steer,Lynne J. Hocking,David M. Reid,P Wordsworth,Pille Harrison,Wendy Thomson,Anne Barton,Jane Worthington	75
12	The ITGAVrs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets 2009 ·Arthritis Research & Therapy ·Jade E. Hollis‐Moffatt,(unknown),Amanda Phipps‐Green,Marilyn E. Merriman,Nicola Dalbeth,Peter Gow,Andrew Harrison,John Highton,P. B. B. Jones,Lisa K. Stamp,Pille Harrison,B P Wordsworth,Tony R. Merriman	13
13	Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis 2008 ·Lara D. Veeken ·Pille Harrison,J. J. Pointon,K Chapman,Andrew Roddam,B P Wordsworth	63
14	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13 2008 ·Nature Genetics ·Anne Barton,Wendy Thomson,Xiayi Ke,Stephen Eyre,Anne Hinks,John Bowes,Darren Plant,Laura J. Gibbons,Anthony G. Wilson,D E Bax,Ann W Morgan,Paul Emery,Sophia Steer,Lynne J. Hocking,David M. Reid,P Wordsworth,Pille Harrison,Jane Worthington	108
15	Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients 2006 ·Lara D. Veeken ·Pille Harrison,J. J. Pointon,C. Farrar,Matthew A. Brown,B. P. Wordsworth	46
16	MHC2TA promoter polymorphism (-168G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients 2006 ·Lara D. Veeken* ·Pille Harrison,J J Pointon,C. Farrar,(unknown),B P Wordsworth	16
17	Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative 2004 ·Lara D. Veeken ·Christos Lampropoulos,Shirish Sangle,Pille Harrison,G. R. V. Hughes,David D’Cruz	56
18	COMPARISON OF FACTOR-VIII CONCENTRATES AND VWFTHP FOR THE TREATMENT OF VONWILLEBRANDS DISEASE 1991 ·UCL Discovery (University College London) ·(unknown),(unknown),Pille Harrison,(unknown),(unknown),G.F. Savidge	1
19	Alzheimer's disease: The significance of a β-amyloid precursor protein gene mutation 1991 ·Pille Harrison,Michael Mullan	1
20	Pharmacokinetics of fenbendazole in dogs 1990 ·Journal of Veterinary Pharmacology and Therapeutics ·Quintin McKellar,Pille Harrison,E.A. Galbraith,(unknown)	36

About Pille Harrison

Pille Harrison is a scholar working on Genetics, Rheumatology and Hematology, having authored 53 papers that have together received 2.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (19 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Chronic Myeloid Leukemia Treatments (9 papers). The work is most often cited by research in Rheumatology (1.0k citations), Hematology (413 citations) and Genetics (359 citations). Pille Harrison has collaborated with scholars based in United Kingdom, Belgium and United States. Frequent co-authors include Chantal Tasset, Annegret Van der Aa, David M. Reid, Anne Barton, Ann W Morgan, Wendy Thomson, Jane Worthington, Lynne J. Hocking, Sophia Steer and P Wordsworth. Their work appears in journals such as The Lancet, Nature Genetics and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact